Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Cholangiocarcinoma × futibatinib × Clear all

Phase

Status

Recruiting 1 Enrolling by invitation 1 Approved for marketing 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 3 Biliary Tract Neoplasms 2 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Sarcoma, Alveolar Soft Part 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Head and Neck Neoplasms 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 19 Cisplatin 16 durvalumab 13 lenvatinib 11 Oxaliplatin 9 pembrolizumab 6 Leucovorin 4 Floxuridine 4 apatinib 3 Taxes 3 Magnetic Resonance Spectroscopy 3 Liver Transplantation 3 Folfox protocol 3 Fluorouracil 3 Drug Therapy 3 Capecitabine 3 Biopsy 3 Albumin-Bound Paclitaxel 3 tremelimumab 2 tislelizumab 2 pemigatinib 2 olaparib 2 ivosidenib 2 irinotecan sucrosofate 2 Yttrium-90 2 Surgical Procedures, Operative 2 Specimen Handling 2 Injections 2 Immunoglobulin G 2 Fluorodeoxyglucose F18 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05727176 2025-12-29

FOENIX-CCA4

Taiho Oncology, Inc.

Phase 2 Recruiting

Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡